Phase II trial of oral vinorelbine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) positive mutation after failure or resistance to treatment with Tyrosine Kinase Inhibitors
Phase II trial of oral vinorelbine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) positive mutation after failure or resistance to treatment with Tyrosine Kinase Inhibitors
NAVOTRIAL 2
Phase II trial of oral vinorelbine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) positive mutation after failure or resistance to treatment with Tyrosine Kinase Inhibitors (TKI) in first line
Status
Status :
Completed
Type of study
Phase II
Min. Age
18
Years old
Max. Age
85
Years old
Gender
All
Therapeutic area :
Oncology
Disease :
Non small cell lung cancer (NSCLC)
Study medication :
Vinorelbine (Navelbine® Oral)
Phase :
Phase II
Start Date :
01 December 2012
End date :
17 April 2015
Study ID :
PM0259 CA 229 J1
EudraCT/CTIS number :
2012-003361-18
Send by email